{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:59:16Z","timestamp":1793771956802,"version":"4.6.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.msard.2025.106619","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:41:10Z","timestamp":1752712870000},"page":"106619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Systematic review on the wearing-off phenomenon of disease-modifying therapies in managing multiple sclerosis"],"prefix":"10.1016","volume":"102","author":[{"given":"Aliu O.","family":"Yakubu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olorungbami Kolade","family":"Anifalaje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwakemi Eunice","family":"Olalude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francess Oluwaferanmi","family":"Adeyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreoluwa","family":"Morakinyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmalik O.","family":"Makanjuola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106619_bib0001","series-title":"StatPearls","article-title":"Natalizumab","author":"Babaesfahani","year":"2025"},{"key":"10.1016\/j.msard.2025.106619_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.122930","article-title":"Natalizumab extended dosing : what about wearing-off effect?","volume":"458","author":"Bernardes","year":"2024","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2025.106619_bib0003","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000678","article-title":"Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy","volume":"7","author":"Bringeland","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106619_bib26","doi-asserted-by":"crossref","first-page":"117622","DOI":"10.1016\/j.jns.2021.117622","article-title":"Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic","volume":"429","author":"Bringeland","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106619_bib27","doi-asserted-by":"crossref","first-page":"116880","DOI":"10.1016\/j.jns.2020.116880","article-title":"Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: A prospective 1-year follow-up study","volume":"415","author":"Bringeland","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106619_bib28","doi-asserted-by":"crossref","first-page":"102020","DOI":"10.1016\/j.msard.2020.102020","article-title":"End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?","volume":"41","author":"Cath\u00e9rine","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"629","key":"10.1016\/j.msard.2025.106619_bib0004","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3399\/bjgp14X682609","article-title":"What\u2019s new in multiple sclerosis?","volume":"64","author":"Dimitrov","year":"2014","journal-title":"Br. J. Gen. Pract. J. R. Coll. Gen. Pract."},{"issue":"1","key":"10.1016\/j.msard.2025.106619_bib0005","first-page":"27","article-title":"Multiple sclerosis \u2013 a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc."},{"issue":"1","key":"10.1016\/j.msard.2025.106619_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2010.09.005","article-title":"Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis","volume":"93","author":"Dutta","year":"2011","journal-title":"Prog. Neurobiol."},{"issue":"6","key":"10.1016\/j.msard.2025.106619_bib0007","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/bcp.14658","article-title":"Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO","volume":"87","author":"Gibiansky","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.msard.2025.106619_bib0008","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/1756285609337827","article-title":"Monoclonal antibodies in multiple sclerosis treatment: current and future steps","volume":"2","author":"Helliwell","year":"2009","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106619_bib0009","series-title":"Multiple Sclerosis: Current Status and Strategies for the Future","article-title":"Characteristics and management of major symptoms","author":"Joy","year":"2001"},{"issue":"5","key":"10.1016\/j.msard.2025.106619_bib0010","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200185","article-title":"No increase in symptoms toward the end of the ocrelizumab infusion cycle in patients with multiple sclerosis: symptom burden on ocrelizumab: a longitudinal study (SymBOLS): symptom burden on ocrelizumab: a longitudinal study (SymBOLS)","volume":"13","author":"Kister","year":"2023","journal-title":"Neurol. Clin. Pract."},{"issue":"102585","key":"10.1016\/j.msard.2025.106619_bib0011","article-title":"A longitudinal study of symptom botheration in Multiple Sclerosis","volume":"46","author":"Kister","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106619_bib0012","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00415-022-11408-0","article-title":"Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic","volume":"270","author":"Magro","year":"2023","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106619_bib0013","article-title":"The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis","volume":"10","author":"Marian","year":"2024","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"8","key":"10.1016\/j.msard.2025.106619_bib0014","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1007\/s00415-024-12434-w","article-title":"The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis","volume":"271","author":"Monteiro","year":"2024","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106619_bib0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/XEB.0000000000000064","article-title":"Conducting systematic reviews of association (etiology): the Joanna Briggs Institute\u2019s approach","volume":"13","author":"Moola","year":"2015","journal-title":"Int. J. Evid. Based Healthc."},{"key":"10.1016\/j.msard.2025.106619_bib0016","series-title":"JBI Manual for Evidence Synthesis","article-title":"Chapter 7: systematic reviews of etiology and risk","author":"Moola","year":"2020"},{"issue":"15","key":"10.1016\/j.msard.2025.106619_bib0017","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.2169\/internalmedicine.56.7667","article-title":"The risk factors for the wearing-off phenomenon in Parkinson\u2019s disease in japan: a cross-sectional, multicenter study","volume":"56","author":"Ouma","year":"2017","journal-title":"Intern. Med."},{"key":"10.1016\/j.msard.2025.106619_bib0018","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"10.1016\/j.msard.2025.106619_bib0019","article-title":"Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience","volume":"14","author":"Perncezky","year":"2022","journal-title":"J. Cent. Nerv. Syst. Dis."},{"issue":"17","key":"10.1016\/j.msard.2025.106619_bib0020","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2025.106619_bib0021","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7224\/1537-2073.2013-017","article-title":"Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle","volume":"16","author":"Ratchford","year":"2014","journal-title":"Int. J. MS Care"},{"issue":"105939","key":"10.1016\/j.msard.2025.106619_bib0022","article-title":"Exploring the impact of wearing-off phenomenon in ocrelizumab-treated multiple sclerosis patients: insights from a comprehensive study","volume":"92","author":"Sefero\u011flu","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106619_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103364","article-title":"The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis","volume":"57","author":"Toorop","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106619_bib29","doi-asserted-by":"crossref","unstructured":"Toorop AA, Wessels MHJ, Gelissen LMY, Hoitsma E, Zeinstra EMPE, van Rooij LC, van Munster CEP, Vennegoor A, Mostert JP, Wokke BHA, Kalkers NF, Hoogervorst ELJ, van Eijk JJJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige LGF, Kloosterziel ME, Arnoldus EPJ, van Dijk GW, Bouvy WH, Strijbis EMM, van Oosten BW, de Jong BA, Lissenberg-Witte BI, Rispens T, Uitdehaag BMJ, Killestein J, van Kempen ZLE. Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial. J Neurol Sci. 2024 Jul 15;462:123102. doi:10.1016\/j.jns.2024.123102.","DOI":"10.1016\/j.jns.2024.123102"},{"issue":"17","key":"10.1016\/j.msard.2025.106619_bib0024","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1212\/WNL.0000000000008357","article-title":"The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms","volume":"93","author":"van Kempen","year":"2019","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.msard.2025.106619_bib0025","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500361X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500361X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:25:32Z","timestamp":1780039532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482500361X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":29,"alternative-id":["S221103482500361X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106619","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review on the wearing-off phenomenon of disease-modifying therapies in managing multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106619"}}